Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Wash Sale Impact Dividend Etf Loss Harvest
This piece explains how wash sale rules affect Dividend Etf losses, with practical strategies to stay compliant and preserve tax benefits.
20,231 articles
Why Customer Reviews Matter More to Gen Z Than Influencers
Gen Z is changing the credibility game, leaning on what others say over paid promotions. This article explains why cu...
Powell Says He'll Stay on Fed Board After Chair Term Ends
Powell will continue to serve on the Federal Reserve Board after his chair term ends next month, steering a measured ...
Ripple Joins Crypto ISAC to Share North Korea Intel
Ripple announces a security collaboration with Crypto ISAC to share North Korea-linked threat intel, aiming to streng...
Amazon Might Real Winner From AI Partnership Shakeup
A major reshuffle around Microsoft and OpenAI could shift AI momentum in tech clouds. This article explains why amazo...
Viral Layer-3 Altcoin Rockets After Major Upbit Listing
A Layer-3 token listed on South Korea's Upbit surged in minutes, triggering a rapid rally described by traders as a v...
Secure Your Mask First: The 529 Mistake Parents Make
Financial planners warn that prioritizing 529s over retirement can jeopardize long-term security. This report explain...
Sparks Flare Over Florida Housing Bill Targets Idle Golf Courses
A targeted Florida housing bill aims to convert idle Southeast Florida golf courses into housing, triggering lawsuits...
Caris (CAI) 2026 Earnings: A Clear Investor Roadmap
Caris Life Sciences blends lab testing with AI-driven insights to tackle oncology challenges. This piece breaks down ...
Group (RILY) 2025 Earnings: A Practical Investor’s Guide
This guide helps you understand the drivers behind the group (rily) 2025 earnings for BRC Group under RILY. It breaks...
Axsome Therapeutics Stock Jumped: April Rally and What It Means for Investors
Axsome Therapeutics rode a powerful April rally driven by Auvelity performance and pipeline momentum. This article br...
IonQ Stock Revenue Skyrockets? Is It a Buy Right Now
IonQ just posted revenue that more than tripled for the third straight quarter, but the stock sold off despite the ga...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status